A drug undergoing test as a treatment for cancer could also help reverse autism's behavioral symptoms, says a new study.
Researchers from the University of Edinburgh and McGill University have identified a chemical pathway that goes awry in the brains of Fragile X patients, stated that a cancer drug candidate could reverse their behavioral symptoms and found that a naturally occurring anti-fungal called cercosporamide can block the pathway and improve sociability in mice with the condition.
Autism
Autism is a neurodevelopmental disorder typically characterized by impaired social and communication skills combined with repetitive movements.
Advertisement
The team identified a key molecule - eIF4E - that drives excess protein production in the brains of Fragile X patients. This can cause behavioural symptoms that include learning difficulties. It can also lead to more serious intellectual disabilities, delays in speech and language development and problems with social interactions.
The team found that treatment with cercosporamide blocks the activity of eIF4E, and therefore reduces the amounts of MMP-9, and reverses the behavioural symptoms in mice with a version of Fragile X Syndrome. The new findings suggested that it could have a use as a treatment for patients with Fragile X Syndrome.
![Rett Syndrome]( "Rett Syndrome")
Rett Syndrome is a neurological disorder that affects development. It mostly affects the girl child.
Christos Gkogkas, of the University of Edinburgh's Patrick Wild Centre for Research into Autism, Fragile X Syndrome and Intellectual Disabilities, said that by designing treatments that block just this pathway, it is hoped that they can limit the potential side-effects and develop therapies that are more efficient than general treatment approaches.
The study is published in the journal Cell Reports.
Source: ANI
Rett Syndrome
Rett Syndrome is a neurological disorder that affects development. It mostly affects the girl child.
Advertisement
Christos Gkogkas, of the University of Edinburgh's Patrick Wild Centre for Research into Autism, Fragile X Syndrome and Intellectual Disabilities, said that by designing treatments that block just this pathway, it is hoped that they can limit the potential side-effects and develop therapies that are more efficient than general treatment approaches.
The study is published in the journal Cell Reports.
Source: ANI
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The impact of anti-obesity drugs on survival rates among osteoarthritis patients is under scrutiny, evaluating their potential influence on mortality risks.
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.